U.S. Markets closed

Illumina paid steep price for Verinata, says Oppenheimer

After Illumina agreed to buy Verinata for $350M in cash and up to $100M in milestones, Oppenheimer thinks the deal is "appropriately aggressive." However, the firm views Verinata as the least differentiated player in the T21 testing sector and it maintains a Perform rating on Illumina.